Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus

Cancer Research

Volumn 65, Issue 24, 2005, Pages 11255-11258

  Kambara, Hirokazu ^a   Saeki, Yoshinaga ^a   Chiocca, E Antonio ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CANCER THERAPY; CONTROLLED STUDY; DRUG EFFECT; GLIOMA; HERPES SIMPLEX VIRUS 1; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME; VIROTHERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; GENE THERAPY; GENETIC VECTORS; GLIOMA; HERPESVIRUS 1, HUMAN; HUMANS; MICE; ONCOLYTIC VIRUSES; SURVIVAL RATE; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 29244442698     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2278     Document Type: Article

References (15)

1. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002;2:938-50.
2. Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005;65:2832-9.
3. Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004;10: 958-66.
4. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001;8:89-98.
5. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74.
6. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001;8:746-59.
7. Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002;20:2251-66.
8. Rampling R. Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7: 859-66.
9. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002;62:6070-9.
10. Ikeda K, Wakimoto H, Ichikawa T, et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication- conditional herpes simplex virus mutant. J Virol 2000;74: 4765-75.
11. Wakimoto H, Ikeda K, Abe T, et al. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther 2002;5:275-82.
12. Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999;5:881-7.
13. Wakimoto H, Fulci G, Tyminski E, Chiocca EA. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther 2004;11:214-23.
14. Aguilar LK, Aguilar-Cordova E. Evolution of a gene therapy clinical trial. From bench to bedside and back. J Neurooncol 2003;65:307-15.
15. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994;91:7727-31.